Retension Pharmaceuticals, Inc. - Common Stock (RTSN)

Retension (NASDAQ: RTSN), a clinical-stage biopharmaceutical company developing treatments for hypertension and other cardiovascular diseases, announced the pricing of its upsized initial public offering of 3,750,000 shares of common stock at $12 per share, generating expected gross proceeds of $45 million before underwriting discounts, commissions and other offering expenses. The company granted underwriters a 30-day option to purchase up to an additional 562,500 shares. Retension shares were expected to begin trading on the Nasdaq Capital Market on Oct. 9, 2026, with the offering scheduled to close on or about Oct. 13, subject to customary closing conditions.